Next Article in Journal
Amphipathic Peptides Impede Lipid Domain Fusion in Phase-Separated Membranes
Next Article in Special Issue
Synthetic Poly(lactic-co-glycolic Acid) Microvesicles as a Feasible Carbon Monoxide-Releasing Platform for Cancer Treatment
Previous Article in Journal
Biphenyl-Based Covalent Triazine Framework/Matrimid® Mixed-Matrix Membranes for CO2/CH4 Separation
Previous Article in Special Issue
Toxicological Profile of Umbilical Cord Blood-Derived Small Extracellular Vesicles
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Membranes
Volume 11
Issue 10
10.3390/membranes11100796
Review Report
membranes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapy for Alzheimer’s Disease: Progress and Opportunity

Membranes 2021, 11(10), 796; https://doi.org/10.3390/membranes11100796
by Yi-An Chen 1,2, Cheng-Hsiu Lu 3,4, Chien-Chih Ke 5,6,7 and Ren-Shyan Liu 1,8,9,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Membranes 2021, 11(10), 796; https://doi.org/10.3390/membranes11100796
Submission received: 23 September 2021 / Revised: 16 October 2021 / Accepted: 16 October 2021 / Published: 19 October 2021
(This article belongs to the Special Issue Shedding New Light on the Cell Biology and Medicine of Extracellular Vesicles)

Round 1

Reviewer 1 Report

This review aims to present recent progress on the therapeutic potential of EVs derived from mesenchymal stem cells (MSCs) in the treatment of AD, yet only 38% of the cited references are from 2019-2021 period. I believe at least 50% would be more appropriate to offer a perspective on the newest discoveries (e.g., Adv. Drug Deliv. Rev. 174, 535-552, 2021; Sci. Rep. 11, 18518, 2021; Alz. Res. Therapy 13, 57, 2021)

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

In the manuscript, the authors discuss the perspectives of using mesenchymal stem cell-derived extracellular vesicles for treatment or alleviation of Alzheimer’s Disease. The introduction gives a detail-rich overview of the molecular remedies currently used or under development.

The EVs characteristics and recommendations for characterization are further on described.   The currently known action mechanisms are discussed and the manuscript includes a table with current preclinical studies toward using stem cell-derived EVs in the treatment of AD. Aß plaques increased clearance mechanism and/or supposed implication of EVs, the neuroprotection and immunomodulation are three sets of data presented that build a panel of molecular mechanisms in which the stem cells, including mesenchimal stromal cells, may be involved. A chapter describing current clinical studies and strategies for EV therapies ends the review.

The manuscript is well balanced in the structure of chapters and in the weight of specific data, both medical and cellular mechanisms. An in-depth systematization of the best current practices, based on the results of the preclinical and clinical studies and/or on type of stem cells/EVs characterization would be a benefit of chapter 7.

Anyhow, the first clinical trial presented in table 2 is the only example EVs (precisely exosomes) tested for treatment of AD. Hence, the conclusion of the review seems to be bold (lines 401-402, 412-414).

Lines 81-82 would need a citation.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop